ARGX
argenx SE
There isn't enough reported data to score ARGX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ARGX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ARGX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ARGX PE Valuation
ARGX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ARGX Forward outlook
There aren't enough analyst estimates for ARGX to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ARGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2021 | -$7.99 | +$4.95 |
| Q2 2021 | -$6.52 | +$2.10 |
| Q4 2020 | -$12.94 | -$8.25 |
| Q2 2020 | -$8.62 | -$5.78 |
| Q4 2019 | -$4.69 | -$2.48 |
| Q4 2018 | -$2.21 | -$0.94 |
ARGX lost $7.99 per share over the past year, a bigger loss than the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over ARGX in the latest year-over-year earnings comparison.
ARGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2021 | $497.3M | +3089% |
| Q2 2021 | $470.4M | +1791% |
| Q4 2020 | $15.6M | -47% |
| Q2 2020 | $24.9M | -49% |
| Q4 2019 | $29.2M | +635% |
| Q2 2019 | $48.4M | +143% |
| Q4 2018 | $4M | -90% |
| Q4 2017 | $40.5M | +275% |
ARGX has the edge over HIMS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2021 | -70% | +403 points |
| Q2 2021 | 20% | +145 points |
| Q4 2020 | -1541% | +39 points |
| Q2 2020 | -900% | -758 points |
| Q4 2019 | -473% | -410 points |
| Q2 2019 | -125% | +20 points |
| Q4 2018 | -1581% | -1475 points |
| Q2 2018 | -142% | -4.6 points |
ARGX's operating margin was −70% last quarter, up 403 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ARGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2021 | -$610.4M | -$376.4M |
| Q2 2021 | -$227.5M | -$75.6M |
| Q4 2020 | -$234M | -$128.8M |
| Q2 2020 | -$151.8M | -160% |
| Q4 2019 | -$105.2M | -$75.7M |
| Q2 2019 | $253M | +$283.9M |
| Q4 2018 | -$29.5M | +$11.5M |
| Q4 2017 | -$41M | -$28.2M |
ARGX has burned cash in most quarters: −$1.2B over the past year, against $87M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ARGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +437K shares |
| 1 year | +32% | +12.5M shares |
| 3 years | +225% | +35.4M shares |
ARGX has 51M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2016 | — |
| Q2 2016 | — |
| Q4 2015 | — |
| Q2 2015 | — |
| Q4 2014 | — |
| Q2 2014 | — |
| Q4 2013 | — |
| Q2 2013 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ARGX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ARGX Net Leverage
ARGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ARGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 51.3 | Neutral |
ARGX's weekly RSI is 58 (neutral) and its Stochastic is 51 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ARGX PE vs Healthcare Sector
ARGX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ARGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $899.8 | 9.1% above |
| 20 week MA | $921.8 | 6.5% above |
| 50 week MA | $855.0 | 15% above |
| 100 week MA | $759.7 | 29% above |
| 200 week MA | $602.7 | 63% above |
ARGX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ARGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $160.8 | $299.5 | +86% |
| 2021 | $299.5 | $350.0 | +17% |
| 2022 | $350.0 | $377.3 | +7.8% |
| 2023 | $377.3 | $380.4 | +0.8% |
| 2024 | $380.4 | $626.3 | +65% |
| 2025 | $626.3 | $844.9 | +35% |
| 2026 YTD | $844.9 | $981.3 | +16% |
ARGX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.